vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $34.3M, roughly 1.7× Clearfield, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs -3.2%). Clearfield, Inc. produced more free cash flow last quarter ($-2.4M vs $-167.0M).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
CLFD vs PHAT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $57.6M |
| Net Profit | $-614.0K | — |
| Gross Margin | 33.2% | 86.7% |
| Operating Margin | -5.3% | — |
| Net Margin | -1.8% | — |
| Revenue YoY | -3.2% | 94.1% |
| Net Profit YoY | 67.8% | 71.6% |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | $57.6M | ||
| Q3 25 | $23.4M | $49.5M | ||
| Q2 25 | $49.9M | $39.5M | ||
| Q1 25 | $47.2M | $28.5M | ||
| Q4 24 | $29.7M | $29.7M | ||
| Q3 24 | $5.6M | $16.4M | ||
| Q2 24 | $48.8M | $7.3M | ||
| Q1 24 | $36.9M | — |
| Q4 25 | $-614.0K | — | ||
| Q3 25 | $-9.1M | $-30.0M | ||
| Q2 25 | $1.6M | $-75.8M | ||
| Q1 25 | $1.3M | $-94.3M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | — | $-85.6M | ||
| Q2 24 | $-447.0K | $-91.4M | ||
| Q1 24 | $-5.9M | — |
| Q4 25 | 33.2% | 86.7% | ||
| Q3 25 | 53.2% | 87.5% | ||
| Q2 25 | 30.5% | 87.2% | ||
| Q1 25 | 30.1% | 86.9% | ||
| Q4 24 | 29.2% | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | 21.9% | 81.2% | ||
| Q1 24 | 7.7% | — |
| Q4 25 | -5.3% | — | ||
| Q3 25 | 10.3% | -30.8% | ||
| Q2 25 | 3.0% | -151.7% | ||
| Q1 25 | 0.6% | -276.5% | ||
| Q4 24 | -6.9% | — | ||
| Q3 24 | — | -433.0% | ||
| Q2 24 | -4.7% | -1055.4% | ||
| Q1 24 | -26.4% | — |
| Q4 25 | -1.8% | — | ||
| Q3 25 | -38.8% | -60.5% | ||
| Q2 25 | 3.2% | -191.9% | ||
| Q1 25 | 2.8% | -330.7% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | — | -523.3% | ||
| Q2 24 | -0.9% | -1248.6% | ||
| Q1 24 | -16.0% | — |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.65 | $-0.41 | ||
| Q2 25 | $0.11 | $-1.05 | ||
| Q1 25 | $0.09 | $-1.31 | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | — | $-1.32 | ||
| Q2 24 | $-0.04 | $-1.56 | ||
| Q1 24 | $-0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | $249.7M | $-438.2M |
| Total Assets | $268.1M | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | $130.0M | ||
| Q3 25 | $106.0M | $135.2M | ||
| Q2 25 | $117.2M | $149.6M | ||
| Q1 25 | $112.0M | $212.3M | ||
| Q4 24 | $113.0M | $297.3M | ||
| Q3 24 | $129.0M | $334.7M | ||
| Q2 24 | $123.8M | $276.2M | ||
| Q1 24 | $142.9M | — |
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | $2.2M | $175.7M | ||
| Q2 24 | $2.1M | $174.4M | ||
| Q1 24 | — | — |
| Q4 25 | $249.7M | $-438.2M | ||
| Q3 25 | $256.2M | $-422.5M | ||
| Q2 25 | $264.5M | $-405.8M | ||
| Q1 25 | $265.9M | $-338.4M | ||
| Q4 24 | $267.4M | $-253.6M | ||
| Q3 24 | $275.8M | $-187.1M | ||
| Q2 24 | $274.6M | $-233.8M | ||
| Q1 24 | $279.2M | — |
| Q4 25 | $268.1M | $259.1M | ||
| Q3 25 | $306.2M | $240.3M | ||
| Q2 25 | $314.7M | $250.2M | ||
| Q1 25 | $310.9M | $294.2M | ||
| Q4 24 | $303.2M | $378.3M | ||
| Q3 24 | $315.3M | $387.0M | ||
| Q2 24 | $318.1M | $319.4M | ||
| Q1 24 | $315.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $-166.8M |
| Free Cash FlowOCF − Capex | $-2.4M | $-167.0M |
| FCF MarginFCF / Revenue | -7.1% | -290.0% |
| Capex IntensityCapex / Revenue | 2.9% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | $-166.8M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | $7.9M | $-62.7M | ||
| Q1 25 | $3.0M | $-84.9M | ||
| Q4 24 | $7.2M | $-266.8M | ||
| Q3 24 | $22.2M | $-63.6M | ||
| Q2 24 | $4.0M | $-70.7M | ||
| Q1 24 | $-5.7M | — |
| Q4 25 | $-2.4M | $-167.0M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | $7.5M | $-62.8M | ||
| Q1 25 | $654.0K | $-84.9M | ||
| Q4 24 | $5.1M | $-266.9M | ||
| Q3 24 | $18.2M | $-63.6M | ||
| Q2 24 | $2.8M | $-70.8M | ||
| Q1 24 | $-7.7M | — |
| Q4 25 | -7.1% | -290.0% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | 15.1% | -159.0% | ||
| Q1 25 | 1.4% | -297.9% | ||
| Q4 24 | 17.1% | -899.8% | ||
| Q3 24 | 323.0% | -389.0% | ||
| Q2 24 | 5.8% | -966.2% | ||
| Q1 24 | -20.8% | — |
| Q4 25 | 2.9% | 0.4% | ||
| Q3 25 | 2.0% | 0.1% | ||
| Q2 25 | 0.8% | 0.2% | ||
| Q1 25 | 5.1% | 0.1% | ||
| Q4 24 | 7.0% | 0.5% | ||
| Q3 24 | 71.4% | 0.3% | ||
| Q2 24 | 2.5% | 0.6% | ||
| Q1 24 | 5.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
